Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can weaker lung cancer patients handle same powerful treatment?

NCT ID NCT04253964

First seen Mar 23, 2026 · Last updated May 20, 2026 · Updated 10 times

Summary

This study looks at whether non-small cell lung cancer patients with a lower performance status (meaning they are less active or have more symptoms) can benefit from the same first-line chemo/immunotherapy as healthier patients. Researchers will compare how long the cancer stays under control, survival, side effects, and quality of life between the two groups. The goal is to see if it's safe and effective to treat these patients with the same standard regimen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Wake Forest Baptist Comprehensive Cancer Center

    RECRUITING

    Winston-Salem, North Carolina, 27105, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.